Colorectal cancer (CRC) is one of the most lethal cancers, representing around 9% of cancer-related deaths and 10% of new cancer diagnoses worldwide. This genetic disease is characterized by highly heterogeneous genetic profiles which were often used to stratify tumors patients in different classes. In the precision oncology era, the patient stratification by tumor genetic features is essential to guide therapy. During the initial administration of target therapy, tumors can already contain drug-resistant mutant cells which can be selected by drug pressure. Additionally, tumor cells can evade therapeutic pressures by mechanism of adaptive mutability, by enhancing their mutational rate and generating the emergence of new resistance clones.
The aim of this Research Topic is to understand the impact of genetics on CRC therapy. The main focus of the research works would be the emergence and selection of resistance clones as the leading cause of targeted therapies failure based on genetic stratification. This phenomenon is guided by drug selection of pre-existing resistant cells in heterogeneous tumors or by the emergence of new resistance clones through mechanisms of adaptive mutability.
We are interested in manuscripts which address the impact of genetics on CRC therapy. Studies of interest include but are not limited to:
-Genetics and genomics studies in CRC giving new therapeutic options
-The emergence and selection of resistance clones as the leading cause of targeted therapies failure
-New CRC genetic stratification driving new therapeutic treatments
-Drug selection of pre-existing resistant cells in heterogeneous tumors leading cause of targeted therapies failure
-The emergence of new resistance clones through mechanisms of adaptive mutability in CRC.
-Genetic Biomarkers guiding CRC therapy
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Colorectal cancer (CRC) is one of the most lethal cancers, representing around 9% of cancer-related deaths and 10% of new cancer diagnoses worldwide. This genetic disease is characterized by highly heterogeneous genetic profiles which were often used to stratify tumors patients in different classes. In the precision oncology era, the patient stratification by tumor genetic features is essential to guide therapy. During the initial administration of target therapy, tumors can already contain drug-resistant mutant cells which can be selected by drug pressure. Additionally, tumor cells can evade therapeutic pressures by mechanism of adaptive mutability, by enhancing their mutational rate and generating the emergence of new resistance clones.
The aim of this Research Topic is to understand the impact of genetics on CRC therapy. The main focus of the research works would be the emergence and selection of resistance clones as the leading cause of targeted therapies failure based on genetic stratification. This phenomenon is guided by drug selection of pre-existing resistant cells in heterogeneous tumors or by the emergence of new resistance clones through mechanisms of adaptive mutability.
We are interested in manuscripts which address the impact of genetics on CRC therapy. Studies of interest include but are not limited to:
-Genetics and genomics studies in CRC giving new therapeutic options
-The emergence and selection of resistance clones as the leading cause of targeted therapies failure
-New CRC genetic stratification driving new therapeutic treatments
-Drug selection of pre-existing resistant cells in heterogeneous tumors leading cause of targeted therapies failure
-The emergence of new resistance clones through mechanisms of adaptive mutability in CRC.
-Genetic Biomarkers guiding CRC therapy
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.